174022-42-5 Usage
Description
Bevirimat, also known as PA-457, is a pentacyclic triterpenoid derived from the Chinese herb Syzygium claviflorum. It is the first in the class of HIV-1 maturation inhibitors to be studied in humans and has been identified as a potent HIV drug candidate. Bevirimat works by inhibiting the cleavage of the Gag capsid (CA) precursor CA-SP1 to the mature CA protein, thus preventing the replication of drug-sensitive and -resistant clinical isolates of HIV-1.
Uses
Used in Pharmaceutical Industry:
Bevirimat is used as an HIV-1 maturation inhibitor for targeting the Gag CA-SP1 cleavage site. It is employed to inhibit the replication of both drug-sensitive and drug-resistant clinical isolates of HIV-1 in isolated human peripheral blood mononuclear cells (PBMCs), with mean IC50s of 10.3 and 7.8 nM, respectively.
Additionally, Bevirimat is used in HIV treatment:
In vivo, Bevirimat prevents the replication of HIV-1 in SCID-hu Thy/Liv mice when administered at a dose of 100 mg/kg. Despite its potential as a potent HIV drug candidate, the development of Bevirimat into a new drug has been hindered by numerous resistance-related problems.
Enzyme inhibitor
This first-in-class, natural product-based antiviral (FW = 584.83 g/mol; CAS 174022-42-5; Abbreviation: BVM), also known as 3-O-(3',3'- dimethylsuccinyl)betulinate (DSB), 3β-(3-carboxy-3-methyl-butanoyloxy)- lup-20(29)-en-28-oic acid, PA-457, and MPC-4326, is a novel HIV-1 maturation inhibitor that blocks proteolytic processing of the Gag capsid precursor (CA-SP1) into mature capsid (CA) protein. Bevirimat binds to the Gag polypeptide at the CA/SP1 cleavage site. The net result of BVM treatment is the release of immature, noninfectious viral particles. Despite its promising mode of action, about half of all patients have viruses containing genetic polymorphisms in the Gag SP1 (at positions 6 to 8) protein do not respond to BVM treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 174022-42-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,4,0,2 and 2 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 174022-42:
(8*1)+(7*7)+(6*4)+(5*0)+(4*2)+(3*2)+(2*4)+(1*2)=105
105 % 10 = 5
So 174022-42-5 is a valid CAS Registry Number.
174022-42-5Relevant articles and documents
Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents
Kashiwada,Hashimoto,Cosentino,Chen,Garrett,Lee -
, p. 1016 - 1017 (1996)
-
Design and synthesis of basic ionic liquids for the esterification of triterpenic acids
Ressmann, Anna K.,Schneider, Maria,Gaertner, Peter,Weil, Matthias,Bica, Katharina
, p. 139 - 148 (2017/01/17)
Abstract: We present the design and synthesis of Br?nsted-basic ionic liquids and investigate their application in the microwave-assisted esterification of betulinic acid, aiming towards a benign and pyridine-free manufacturing process of the anti-HIV drug, bevirimat. Graphical abstract: [Figure not available: see fulltext.]
SYNTHESIS OF BETULONIC AND BETULINIC ALDEHYDES
-
Page/Page column 8, (2009/05/28)
The present invention provides for methods of selectively converting betulin to betulonic aldehyde. The present invention also provides for methods of selectively converting 3-substituted triterpen-28-ols to the corresponding 3-substituted triterpen-28-carboxaldehydes. Additionally, the present invention provides for methods of preparing betulonic aldehyde, betulonic acid, betulinic acid, and corresponding 3-substituted triterpenes.